AR030391A1 - Composicion para tratar un estado de enfermedad mediado por quimioquinas y el uso de la misma para la manufactura de un medicamento. - Google Patents
Composicion para tratar un estado de enfermedad mediado por quimioquinas y el uso de la misma para la manufactura de un medicamento.Info
- Publication number
- AR030391A1 AR030391A1 ARP000102923A ARP000102923A AR030391A1 AR 030391 A1 AR030391 A1 AR 030391A1 AR P000102923 A ARP000102923 A AR P000102923A AR P000102923 A ARP000102923 A AR P000102923A AR 030391 A1 AR030391 A1 AR 030391A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- alkenyl
- optionally substituted
- aryl
- heteroaryl
- Prior art date
Links
- 201000010099 disease Diseases 0.000 title abstract 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 4
- 230000001404 mediated effect Effects 0.000 title abstract 3
- 238000004519 manufacturing process Methods 0.000 title abstract 2
- 229940126601 medicinal product Drugs 0.000 title 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 7
- 239000001257 hydrogen Substances 0.000 abstract 7
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 abstract 6
- 125000003342 alkenyl group Chemical group 0.000 abstract 6
- 125000001072 heteroaryl group Chemical group 0.000 abstract 6
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 5
- 108010012236 Chemokines Proteins 0.000 abstract 5
- 102000019034 Chemokines Human genes 0.000 abstract 5
- 125000000027 (C1-C10) alkoxy group Chemical group 0.000 abstract 4
- 125000003118 aryl group Chemical group 0.000 abstract 4
- 150000002431 hydrogen Chemical class 0.000 abstract 4
- 108090001007 Interleukin-8 Proteins 0.000 abstract 3
- 125000003545 alkoxy group Chemical group 0.000 abstract 3
- 125000005343 heterocyclic alkyl group Chemical group 0.000 abstract 3
- 125000000623 heterocyclic group Chemical group 0.000 abstract 3
- 125000003107 substituted aryl group Chemical group 0.000 abstract 3
- 125000002853 C1-C4 hydroxyalkyl group Chemical group 0.000 abstract 2
- 125000006374 C2-C10 alkenyl group Chemical group 0.000 abstract 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 2
- 241000700605 Viruses Species 0.000 abstract 2
- 125000005024 alkenyl aryl group Chemical group 0.000 abstract 2
- 125000005217 alkenylheteroaryl group Chemical group 0.000 abstract 2
- 125000002877 alkyl aryl group Chemical group 0.000 abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 125000004104 aryloxy group Chemical group 0.000 abstract 2
- 150000001540 azides Chemical class 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 2
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 150000002367 halogens Chemical class 0.000 abstract 2
- 125000004446 heteroarylalkyl group Chemical group 0.000 abstract 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 201000001320 Atherosclerosis Diseases 0.000 abstract 1
- 241000711549 Hepacivirus C Species 0.000 abstract 1
- 241000700721 Hepatitis B virus Species 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 208000001132 Osteoporosis Diseases 0.000 abstract 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 1
- 230000033115 angiogenesis Effects 0.000 abstract 1
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 208000007565 gingivitis Diseases 0.000 abstract 1
- 230000003394 haemopoietic effect Effects 0.000 abstract 1
- 208000006454 hepatitis Diseases 0.000 abstract 1
- 231100000283 hepatitis Toxicity 0.000 abstract 1
- 208000002672 hepatitis B Diseases 0.000 abstract 1
- 125000005842 heteroatom Chemical group 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 201000004792 malaria Diseases 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 239000001301 oxygen Substances 0.000 abstract 1
- 230000000241 respiratory effect Effects 0.000 abstract 1
- 208000037803 restenosis Diseases 0.000 abstract 1
- 229910052717 sulfur Chemical group 0.000 abstract 1
- 239000011593 sulfur Chemical group 0.000 abstract 1
- 241001529453 unidentified herpesvirus Species 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Physical Education & Sports Medicine (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Vascular Medicine (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Biotechnology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
- Quinoline Compounds (AREA)
Abstract
Composicion para tratar un estado de enfermedad mediado con quimioquinas, seleccionado del grupo que consiste en malaria, restenosis, angiogénesis, aterosclerosis, osteoporosis, gingivitis, liberacion no deseada de células pluripotenciales hematopoyéticas y enfermedades provocadas por virus respiratorios, herpesvirus y virus de la hepatitis, que incluyen pero sin limitarse al virus de la hepatitis B y de la hepatitis C, en las cuales la quimioquina se une al receptor de IL-8 a o b en un mamífero, que comprende una cantidad eficaz de un compuesto de formula (1) en la cual X es oxígeno o azufre; R es cualquier resto funcional que tiene un hidrogeno ionizable y un pKa de 10 o menos; R1 se selecciona independientemente entre hidrogeno, halogeno, nitro, ciano, alquilo C1-10 halosustituido; alquilo C1-10, alquenilo C2-10; alcoxi C1-10; alcoxi C1-10 halosustituido; azida, S(O)tR4; hidroxi; hidroxialquilo C1-4; arilo; alquil (C1-4)arilo; ariloxi, alquiloxi (C1-4)arilo; heteroarilo, heteroarilalquilo; alquilo C1-4 heterocíclico; alquiloxi (C1-4)heteroarilo; alquenil (C2-10)arilo; alquenil (C2-10)heteroarilo; alquenilo C2-10 heterocíclico; NR4R5; alquenilo C2-10-C(O)NR4R5; C(O)NR4R5; C(O)NR4R10; S(O)3H; S(O)3R8; alquilo C1-10-C(O)R11; alquenilo C2-10-C(O)R11; alquenilo C2-10-C(O)OR11; C(O)R11; C(O)OR12; OC(O)R11; NR4C(O)R11; o dos restos R1 juntos pueden formar O-(CH2)sO- o un anillo insaturado de 5 a 6 eslabones; t es 0 o un numero entero que tiene un valor de 1 o 2; s es un numero entero que tiene un valor de 1 a 3; R4 y R5 son independientemente hidrogeno; alquilo C1-4 opcionalmente sustituido, arilo opcionalmente sustituido, alquil(C1-4)arilo opcionalmente sustituido, heteroarilo opcionalmente sustituido, alquil (C1-4) heteroarilo opcionalmente sustituido, o alquilo C1-4 heterocíclico, heterocíclico, o R4 y R5 junto con el nitrogeno al que están unidos forman un anillo de 5 a 7 eslabones que puede comprender opcionalmente otro heteroátomo seleccionado entre O/N/S; Y se selecciona independientemente entre hidrogeno, halogeno, nitro, ciano, alquilo C1-10 halosustituido; alquilo C1-10; alquenilo C2-10; alcoxi C1-10; alcoxi C1-10 halosustituido; azida, S(O)tR4; hidroxi; hidroxialquilo C1-4; arilo; alquil (C1-4)arilo; ariloxi, alquiloxi (C1-4) arilo; heteroarilo; heteroarilalquilo; alquiloxi (C1-4); heteroarilo; alquilo C1-4 heterocíclico; heterocíclico; alquenil(C2-10) arilo; alquenil (C2-10)heteroarilo; alquenilo C2-10 heterocíclico; NR4R5; alquenilo C2-10-C(O)NR4R5; C(O)NR4R5; C(O)NR4R10; S(O)3H; S(O)3R8; alquilo C1-10-C(O)OR11; alquenilo C2-10-C(O)R11; alquenilo C2-10-C(O)OR11; C(O)R11; C(O)OR12; OC(O)R11; NR4C(O)R11; o dos restos Y juntos pueden formar O-(CH2)sO- o un anillo insaturado de 5 a 6 eslabones; n es un numero entero que tiene un valor de 1 o 3; m es un numero entero que tiene un valor de 1 a 3; R8 es hidrogeno o alquilo C1-10; R10 es alquilo C1-10-C(O)2R8; R11 es hidrogeno, alquilo C1-4, arilo opcionalmente sustituido, alquil (C1-4)arilo opcionalmente sustituido; heteroarilo opcionalmente sustituido, alquil(C1-4)heteroarilo opcionalmente sustituido, heterociclo opcionalmente sustituido, o alquilo C1-4 heterocíclico opcionalmente sustituido; R12 es hidrogeno, alquilo C1-10, arilo opcionalmente sustituido o arilalquilo opcionalmente sustituido; o su sal farmacéuticamente aceptable; el uso de dicha composicion para la manufactura de un medicamento para tratar una enfermedad mediada por quimioquinas, en la cual la quimioquina se une a un receptor de IL-8 a o b, y que comprende administrar una cantidad eficaz de un compuesto de formula (1), o su sal farmacéuticamente aceptable. En particular la quimioquina es IL-8.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13967599P | 1999-06-16 | 1999-06-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR030391A1 true AR030391A1 (es) | 2003-08-20 |
Family
ID=22487790
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP000102923A AR030391A1 (es) | 1999-06-16 | 2000-06-14 | Composicion para tratar un estado de enfermedad mediado por quimioquinas y el uso de la misma para la manufactura de un medicamento. |
Country Status (20)
| Country | Link |
|---|---|
| EP (1) | EP1185261A4 (es) |
| JP (1) | JP2003501459A (es) |
| KR (1) | KR20020010709A (es) |
| CN (1) | CN1355697A (es) |
| AR (1) | AR030391A1 (es) |
| AU (1) | AU766083B2 (es) |
| BR (1) | BR0010802A (es) |
| CA (1) | CA2377341A1 (es) |
| CO (1) | CO5200760A1 (es) |
| CZ (1) | CZ20014471A3 (es) |
| HK (1) | HK1044483A1 (es) |
| HU (1) | HUP0201571A3 (es) |
| IL (1) | IL145761A0 (es) |
| MX (1) | MXPA01013004A (es) |
| NO (1) | NO20016053L (es) |
| NZ (1) | NZ514695A (es) |
| PL (1) | PL352232A1 (es) |
| TR (1) | TR200103680T2 (es) |
| WO (1) | WO2000076495A1 (es) |
| ZA (1) | ZA200109479B (es) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7521479B2 (en) * | 2001-04-16 | 2009-04-21 | Panacea Pharmaceuticals, Inc. | Methods of treating prion disease in mammals |
| GB0201882D0 (en) * | 2002-01-28 | 2002-03-13 | Novartis Ag | Organic compounds |
| IL166040A0 (en) * | 2002-08-01 | 2006-01-15 | Neurosearch As | Compounds useful for the treatment of diseases responsive to antiangiogenetic therapy |
| CA2565519A1 (en) * | 2004-05-12 | 2005-12-01 | Schering Corporation | Cxcr1 and cxcr2 chemokine antagonists |
| US7550499B2 (en) | 2004-05-12 | 2009-06-23 | Bristol-Myers Squibb Company | Urea antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions |
| TW200600492A (en) | 2004-05-18 | 2006-01-01 | Achillion Pharmaceuticals Inc | Substituted aryl acylthioureas and related compounds; inhibitors of viral replication |
| JP2008517930A (ja) | 2004-10-21 | 2008-05-29 | トランス テック ファーマ，インコーポレイテッド | ＧａｌＲ１のアゴニストとしてのビススルホンアミド化合物、組成物、及び使用法 |
| MX2007008434A (es) | 2005-01-19 | 2007-07-25 | Squibb Bristol Myers Co | Derivados de 2-fenoxi-n-(1,3,4-tiadizol-2il)piridin-3-amina y compuestos relacionados como inhibidores del receptor p2y1 para el tratamiento de trastornos tromboembolicos. |
| WO2006089871A2 (en) * | 2005-02-23 | 2006-08-31 | Neurosearch A/S | Diphenylurea derivatives useful as erg channel openers for the treatment of cardiac arrhythmias |
| ES2360818T3 (es) | 2005-06-27 | 2011-06-09 | Bristol-Myers Squibb Company | Miméticos de urea lineal antagonistas del receptor p2y, útiles en el tratamiento de afecciones trombóticas. |
| WO2007002635A2 (en) | 2005-06-27 | 2007-01-04 | Bristol-Myers Squibb Company | C-linked cyclic antagonists of p2y1 receptor useful in the treatment of thrombotic conditions |
| US7728008B2 (en) | 2005-06-27 | 2010-06-01 | Bristol-Myers Squibb Company | N-linked heterocyclic antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions |
| WO2007002634A1 (en) | 2005-06-27 | 2007-01-04 | Bristol-Myers Squibb Company | Carbocycle and heterocycle antagonists of p2y1 receptor useful in the treatment of thrombotic conditions |
| US7960569B2 (en) | 2006-10-17 | 2011-06-14 | Bristol-Myers Squibb Company | Indole antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions |
| JP2008184403A (ja) * | 2007-01-29 | 2008-08-14 | Japan Health Science Foundation | 新規ｃ型肝炎ウイルス阻害剤 |
| KR100982661B1 (ko) * | 2008-04-22 | 2010-09-17 | 전남대학교산학협력단 | 플라스멥신 ⅱ 활성을 저해하는 화합물을 유효성분으로함유하는 말라리아 예방 및 치료를 위한 약학 조성물 및이를 이용한 말라리아 치료방법 |
| KR100970940B1 (ko) * | 2010-05-03 | 2010-07-20 | 전남대학교산학협력단 | 플라스멥신 ⅱ 활성을 저해하는 화합물을 유효성분으로 함유하는 말라리아 예방 및 치료를 위한 약학 조성물 및 이를 이용한 말라리아 치료방법 |
| US10093617B1 (en) * | 2015-10-30 | 2018-10-09 | Sumitomo Chemical Company, Limited | Method for producing 2-amino-4-substituted phenol |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA921120B (en) * | 1991-02-19 | 1993-01-27 | Smithkline Beecham Corp | Cytokine inhibitors |
| JPH11503110A (ja) * | 1995-02-17 | 1999-03-23 | スミスクライン・ビーチャム・コーポレイション | Ｉｌ−８受容体拮抗剤 |
| WO2000016768A1 (en) * | 1998-09-18 | 2000-03-30 | Smithkline Beecham Corporation | Cxcr2 inhibitors and pmn adhesion and t-cell chemotaxis |
-
2000
- 2000-06-13 CO CO00043844A patent/CO5200760A1/es not_active Application Discontinuation
- 2000-06-14 AR ARP000102923A patent/AR030391A1/es not_active Application Discontinuation
- 2000-06-15 NZ NZ514695A patent/NZ514695A/en unknown
- 2000-06-15 HU HU0201571A patent/HUP0201571A3/hu unknown
- 2000-06-15 CN CN00809045A patent/CN1355697A/zh active Pending
- 2000-06-15 KR KR1020017016142A patent/KR20020010709A/ko not_active Application Discontinuation
- 2000-06-15 MX MXPA01013004A patent/MXPA01013004A/es unknown
- 2000-06-15 EP EP00942843A patent/EP1185261A4/en not_active Withdrawn
- 2000-06-15 CZ CZ20014471A patent/CZ20014471A3/cs unknown
- 2000-06-15 CA CA002377341A patent/CA2377341A1/en not_active Abandoned
- 2000-06-15 TR TR2001/03680T patent/TR200103680T2/xx unknown
- 2000-06-15 WO PCT/US2000/016499 patent/WO2000076495A1/en not_active Application Discontinuation
- 2000-06-15 PL PL00352232A patent/PL352232A1/xx not_active Application Discontinuation
- 2000-06-15 IL IL14576100A patent/IL145761A0/xx unknown
- 2000-06-15 AU AU57413/00A patent/AU766083B2/en not_active Ceased
- 2000-06-15 JP JP2001502828A patent/JP2003501459A/ja not_active Withdrawn
- 2000-06-15 BR BR0010802-2A patent/BR0010802A/pt not_active IP Right Cessation
-
2001
- 2001-11-16 ZA ZA200109479A patent/ZA200109479B/en unknown
- 2001-12-11 NO NO20016053A patent/NO20016053L/no not_active Application Discontinuation
-
2002
- 2002-08-22 HK HK02106188.7A patent/HK1044483A1/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CZ20014471A3 (cs) | 2002-08-14 |
| HUP0201571A2 (en) | 2002-08-28 |
| CO5200760A1 (es) | 2002-09-27 |
| EP1185261A1 (en) | 2002-03-13 |
| NZ514695A (en) | 2004-05-28 |
| PL352232A1 (en) | 2003-08-11 |
| AU5741300A (en) | 2001-01-02 |
| MXPA01013004A (es) | 2002-07-30 |
| JP2003501459A (ja) | 2003-01-14 |
| KR20020010709A (ko) | 2002-02-04 |
| NO20016053D0 (no) | 2001-12-11 |
| CN1355697A (zh) | 2002-06-26 |
| TR200103680T2 (tr) | 2002-07-22 |
| HUP0201571A3 (en) | 2002-11-28 |
| CA2377341A1 (en) | 2000-12-21 |
| NO20016053L (no) | 2001-12-11 |
| ZA200109479B (en) | 2002-11-18 |
| HK1044483A1 (zh) | 2002-10-25 |
| WO2000076495A1 (en) | 2000-12-21 |
| EP1185261A4 (en) | 2004-02-25 |
| IL145761A0 (en) | 2002-07-25 |
| AU766083B2 (en) | 2003-10-09 |
| BR0010802A (pt) | 2002-02-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR030391A1 (es) | Composicion para tratar un estado de enfermedad mediado por quimioquinas y el uso de la misma para la manufactura de un medicamento. | |
| AR005706A1 (es) | Inhibidores egfr de 4-aminoquinzolina, procedimiento para su obtencion, composicion farmaceutica que los contiene, uso de los mismos para lapreparacion de un medicamento util como agente antineoplasico | |
| PT1404347E (pt) | Nucleosidos 4'-substituidos para o tratamento de doencas mediadas pelo virus da hepatite c | |
| TR200002761T2 (tr) | HIV enfeksiyonlarının tedavisi için üç-ikameli 1,3,5-triazin türevleri. | |
| CY1116103T1 (el) | Υποκατεστημενα παραγωγα 1,2,3,4-τετραϋδροϊσοκινολινης | |
| CO5031286A1 (es) | Compuestos de ciano guanadina como antagonistas de los receptores de il-8 y metodo de preparacion | |
| PE20020589A1 (es) | 5-espiropirimidin-2,4,6-triona como inhibidores de metaloproteinasas | |
| AR035668A1 (es) | Imidazoquinolinas y 6,7,8,9-tetrahidroimidazoquinolinas, composiciones farmaceuticas que las comprenden, uso de dichos compuestos en la preparacion de medicamentos, e intermediarios utiles en la sintesis de dichos compuestos | |
| MY128463A (en) | 4' substituted nucleosides for the treatment of diseases mediated by the hepatitis c virus | |
| HUP0101999A2 (hu) | 4-Hidroxi-kinolin-3-karboxamid- és -hidrazid-származékok, ezeket tartalmazó gyógyászati készítmények, valamint e vegyületek alkalmazása | |
| CY1105035T1 (el) | Συγχωνευμενα με αρυλιο ή ετεροαρυλιο παραγωγα της ιμιδαζολης ως αντιφλεγμονωδεις και αναλγητικοι παραγοντες | |
| AR039189A1 (es) | Compuesto de pirrolopiridazina, composicion farmaceutica que lo comprende y su uso para preparar dicha composicion | |
| PE20001485A1 (es) | Derivados de la camptotecina que tienen actividad antitumoral | |
| ECSP045073A (es) | Nuevos derivados de piperazina | |
| TW427887B (en) | Pharmaceutical composition comprising a benzimidazole derivative for treating viral infections | |
| AR049405A1 (es) | Compuesto de dicetopiperazina, composicion farmaceutica que lo comprende, uso del compuesto para la fabricacion de un medicamento y procedimiento para la preparacion del mismo | |
| AR038818A1 (es) | Compuesto de piperidina, uso del mismo para preparar un medicamento, composicion farmaceutica que lo comprende y procedimiento para su preparacion | |
| AR033803A1 (es) | Compuestos de dianilino escuarano, composiciones farmaceuticas que los comprenden, y el uso de los mismos en la fabricacion de medicamentos para tratar enfermedades mediadas por quimioquinas | |
| AR037931A1 (es) | Metodo para granulacion humeda de azitromicina | |
| ATE233754T1 (de) | Diphenyl-piperidin derivate | |
| AR037940A1 (es) | Compuestos antivirales de piridoquinoxalina | |
| CO4820432A1 (es) | Composiciones farmaceuticas para el tratamiento de rinitis que comprenden acido 2-(4-(difenilmetil)-1-piperacinil)-ace- tico o amida derivada y un compuesto seleccionado de pseudoe fedrina,fenilpropanolamina y fenilefrina | |
| BR0107912A (pt) | Composto, composições, e, métodos para tratar ou prevenir o c ncer ou doença neoplástica, método para inibir o desenvolvimento de uma célula cancerìgena ou célula neoplástica, método para tratar ou prevenir uma infecção viral em um paciente, e para inibir a replicação ou a infectividade de um vìrus | |
| AR030273A1 (es) | Compuestos de hidroxifenil urea sustituidos con sulfonamidas, composiciones farmaceuticas que los comprenden, y uso de los mismos en la fabricacion de medicamentos para tratar una enfermedad mediada por una quimioquina | |
| CO5190696A1 (es) | Antagonistas de los receptores il-8 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |